Twist Bioscience Corporation (NASDAQ:TWST) Shares Purchased by New York State Common Retirement Fund

New York State Common Retirement Fund lifted its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 2.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 452,750 shares of the company's stock after acquiring an additional 10,761 shares during the period. New York State Common Retirement Fund owned 0.76% of Twist Bioscience worth $17,775,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Versant Capital Management Inc grew its stake in Twist Bioscience by 547.2% during the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company's stock worth $27,000 after buying an additional 580 shares during the last quarter. GAMMA Investing LLC grew its stake in Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after buying an additional 303 shares during the last quarter. Banque Transatlantique SA purchased a new position in Twist Bioscience during the 4th quarter worth approximately $43,000. GF Fund Management CO. LTD. purchased a new position in Twist Bioscience during the 4th quarter worth approximately $58,000. Finally, Pallas Capital Advisors LLC purchased a new position in Twist Bioscience during the 1st quarter worth approximately $201,000.

Twist Bioscience Stock Performance

Shares of TWST stock traded down $0.68 during midday trading on Friday, hitting $35.17. The company had a trading volume of 623,909 shares, compared to its average volume of 966,056. The company's 50 day simple moving average is $33.61 and its 200 day simple moving average is $39.59. Twist Bioscience Corporation has a 52-week low of $27.12 and a 52-week high of $60.90. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -10.82 and a beta of 2.41. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.51 and a quick ratio of 4.24.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 54.98% and a negative return on equity of 33.48%. The company had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,678 shares of Twist Bioscience stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $35.76, for a total value of $60,005.28. Following the sale, the chief executive officer directly owned 645,782 shares in the company, valued at $23,093,164.32. The trade was a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Paula Green sold 1,101 shares of Twist Bioscience stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $41,452.65. Following the completion of the sale, the senior vice president owned 129,380 shares in the company, valued at approximately $4,871,157. This trade represents a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 24,961 shares of company stock valued at $877,006. 3.01% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on TWST. The Goldman Sachs Group dropped their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Robert W. Baird dropped their price target on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Barclays dropped their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Guggenheim restated a "buy" rating and set a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. dropped their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $50.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.